<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="table6" position="float"><object-id pub-id-type="doi">10.7554/eLife.28932.016</object-id><label>Table 6.</label><caption><title>Clinical characteristics of the external validation set.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Characteristic</th><th>Polish external validation set <break/>(N&#160;=&#160;51)</th></tr><tr><th valign="bottom">Age, years, median (SD)</th><th valign="bottom">55.5 (16.1)</th></tr></thead><tbody><tr><td colspan="2" valign="bottom">Grade, n (%)</td></tr><tr><td valign="bottom">Borderline</td><td valign="bottom">4 (7.8)</td></tr><tr><td valign="bottom">&#8195;1</td><td valign="bottom">2 (3.9)</td></tr><tr><td valign="bottom">&#8195;2</td><td valign="bottom">7 (13.7)</td></tr><tr><td valign="bottom">&#8195;3</td><td valign="bottom">13 (25.5)</td></tr><tr><td valign="bottom">&#8195;unspecified</td><td valign="bottom">3 (5.9)</td></tr><tr><td valign="bottom">&#8195;Benign</td><td valign="bottom">22 (43.1)</td></tr><tr><td colspan="2" valign="bottom">FIGO Stage, n (%)</td></tr><tr><td valign="bottom">&#8195;I</td><td valign="bottom">7 (13.7)</td></tr><tr><td valign="bottom">&#8195;II</td><td valign="bottom">3 (5.9)</td></tr><tr><td valign="bottom">&#8195;III</td><td valign="bottom">18 (35.3)</td></tr><tr><td valign="bottom">&#8195;IV</td><td valign="bottom">1 (2.0)</td></tr><tr><td valign="bottom">&#8195;Benign</td><td valign="bottom">22 (43.1)</td></tr><tr><td colspan="2" valign="bottom">Histology, n (%)</td></tr><tr><td valign="bottom">&#8195;Serous cystadenoma/cystadenofibroma</td><td valign="bottom">6 (11.8)</td></tr><tr><td valign="bottom">&#8195;Endometrioma/endometriosis</td><td valign="bottom">10 (19.6)</td></tr><tr><td valign="bottom">&#8195;Mature teratoma</td><td valign="bottom">6 (11.8)</td></tr><tr><td valign="bottom">&#8195;Borderline serous tumor</td><td valign="bottom">2 (3.9)</td></tr><tr><td valign="bottom">&#8195;Borderline seromucinous tumor</td><td valign="bottom">2 (3.9)</td></tr><tr><td valign="bottom">&#8195;Serous adenocarcinoma</td><td valign="bottom">4 (7.8)</td></tr><tr><td valign="bottom">&#8195;Mucinous adenocarcinoma</td><td valign="bottom">1 (2.0)</td></tr><tr><td valign="bottom">&#8195;Endometrioid adenocarcinoma</td><td valign="bottom">1 (2.0)</td></tr><tr><td valign="bottom">&#8195;Clear Cell Adenocarcinoma</td><td valign="bottom">9 (17.6)</td></tr><tr><td valign="bottom">&#8195;Mixed adenocarcinoma</td><td valign="bottom">3 (5.9)</td></tr><tr><td valign="bottom">&#8195;Adenocarcinoma unspecified</td><td valign="bottom">7 (13.7)</td></tr></tbody></table></table-wrap>